VIVUS' loss per share estimates narrowed 22% in 2017 in the last 60 days. Courtesy of Pharmboy. If you are still interested in the Medical - Biomedical and Genetics industry, you may instead consider a better-ranked stock - VIVUS, Inc. VVUS. One year VIVUS stock price chart Hola fellow PSW subscribers! - Ilene . VIVUS, Inc. (VVUS), Arena Pharmaceuticals, Inc. (ARNA) & Some Key Catalysts Approaching Published on April 27, 2013 at 7:12 pm by The Motley Fool in News Share Tweet Email At the moment, the stock is trading around $12. VIVUS Inc. (NASDAQ:VVUS) VIVUS Inc. (NASDAQ:VVUS) stock is bouncing off its 52-week lows days after the stock took a dive despite generally meeting analyst expectations in last week’s Q2 financial release.Since that release, VVUS stock has lost around $0.10 per share on heavy volume. Pharmboy discusses Merck, Regeneron, and Vivus and maps out his plans for trading stock and options in these companies. A Look At VIVUS (NASDAQ:VVUS) With the previous 100-day trading volume average of 1.26 million shares, VIVUS (VVUS) recorded a trading volume of 1.19 million shares, as the stock started the trading session at the value of $1.39, in the end touching the price of $1.38 after dropping by -0.72%. The company delivered positive earnings surprises in all four trailing quarters with an average beat of 233.69%. In addition, VIVUS, Inc. saw 24.26% in overturn over the period of a single year with a tendency to cut further gains. VIVUS, Inc. (NASDAQ:VVUS)’s stock has taken a nosedive since it hit $30 per share after the approval of its anti-obesity drug. So it may not be a good decision to keep this stock in your portfolio anymore, at least if you don’t have a long time horizon to wait. Reports are indicating that there were more than several insider trading activities at VIVUS, Inc. (VVUS), starting from Amos John P., who bought 11,000 shares at the price of $4.85 back on Mar 01. The week is finally over, and the fluctuations in the market is making many of us jittery. VVUS Stock Insider Trading. The Pharma Initiative.